29-Jul-2025 7:28 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA, Company, we or us) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0
16-Jul-2025 7:05 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. Im
20-May-2025 7:28 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) to Present at Maxim Groups 2025 Virtual Tech Conference $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Groups virtual conference: 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Hosted by: Maxim Group LLC Date: June 3rd 5th Presentation Time: Tuesday, June 3rd at 11:00AM EDT Location: Virtual (M-Vest Platform) Registration: Click here to
28-Mar-2025 7:01 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter (Q3) of its 2025 fiscal year (FY25), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic part
11-Mar-2025 9:17 PM CST - Business Wire IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its aud
5-Mar-2025 7:01 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference
10-Dec-2024 7:30 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter (Q2) of its 2025 fiscal year (FY25), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "This quarter marks a pivotal chapter for IPA as we unveil our cutting-edge in silico drug discovery tools, designed to revol
3-Dec-2024 7:30 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will ho
4-Nov-2024 7:01 AM CST - Business Wire ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation $IPA #AI--ImmunoPrecise Antibodies Ltd. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPAs latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese
29-Jul-2025 7:28 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA, Company, we or us) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0
16-Jul-2025 7:05 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. Im
20-May-2025 7:28 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) to Present at Maxim Groups 2025 Virtual Tech Conference $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Groups virtual conference: 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Hosted by: Maxim Group LLC Date: June 3rd 5th Presentation Time: Tuesday, June 3rd at 11:00AM EDT Location: Virtual (M-Vest Platform) Registration: Click here to
28-Mar-2025 7:01 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter (Q3) of its 2025 fiscal year (FY25), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic part
11-Mar-2025 9:17 PM CST - Business Wire IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its aud
5-Mar-2025 7:01 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference
10-Dec-2024 7:30 AM CST - Business Wire ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter (Q2) of its 2025 fiscal year (FY25), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "This quarter marks a pivotal chapter for IPA as we unveil our cutting-edge in silico drug discovery tools, designed to revol
3-Dec-2024 7:30 AM CST - Business Wire IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will ho
4-Nov-2024 7:01 AM CST - Business Wire ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation $IPA #AI--ImmunoPrecise Antibodies Ltd. (the Company or IPA) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPAs latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese
